|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Zymeworks
gptkb:Acorda_Therapeutics
gptkb:Nightstar_Therapeutics
|
|
gptkbp:CEO
|
gptkb:Michel_Vounatsos
|
|
gptkbp:clinicalTrials
|
gptkb:Epilepsy
gptkb:Huntington's_disease
Alzheimer's disease
Bipolar disorder
Migraine
Multiple sclerosis
Depression
Parkinson's disease
Post-traumatic stress disorder
Traumatic brain injury
Schizophrenia
Dementia
Spinal cord injury
Amyotrophic lateral sclerosis
Anxiety disorders
Obsessive-compulsive disorder
Autism spectrum disorder
Cognitive impairment
Spinal muscular atrophy
Attention deficit hyperactivity disorder
|
|
gptkbp:collaborations
|
gptkb:Duke_University
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
|
|
gptkbp:drugInterdiction
|
therapeutics
|
|
gptkbp:employees
|
7,000+
|
|
gptkbp:focus
|
neurological diseases
|
|
gptkbp:founded
|
1978
|
|
gptkbp:founder
|
gptkb:M._A._(Marty)_Houghton
|
|
gptkbp:headCoach
|
7,500 (2021)
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_MA
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biogen Inc.
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:market
|
$40 billion (2021)
|
|
gptkbp:partnerships
|
gptkb:Samsung_Bioepis
gptkb:Ionis_Pharmaceuticals
AbbVie
|
|
gptkbp:products
|
gptkb:Nusinersen
Rituximab
Aducanumab
|
|
gptkbp:researchFocus
|
neurodegenerative diseases
neuroinflammation
neuromuscular diseases
neuropsychiatric disorders
|
|
gptkbp:revenue
|
$11.4 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Ionis_Pharmaceuticals
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.biogen.com
|